Lv01
0 积分 2024-09-24 加入
Thrombotic risk in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with CDK 4/6 inhibitors: a meta-analysis
2小时前
待确认
Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4
3小时前
已完结
Phase II Trial of Brain MRI Surveillance in Stage IV Breast Cancer
1个月前
已完结
Pathogenesis, pathological characteristics and individualized therapy for immune-related adverse effects
1个月前
已完结
The significance of highlighting the oestrogen receptor low category in breast cancer
3个月前
已完结
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
4个月前
已完结
Multimorbidity and the risk of malnutrition, frailty and sarcopenia in adults with cancer in the UK Biobank
4个月前
已完结
Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors
4个月前
已完结
Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors
4个月前
已完结
235P The impact of body mass index (BMI) on the progression-free survival of CDK4/6 inhibitors in metastatic breast cancer patients (MBC)
4个月前
已完结
皖公网安备34019202002308
